DIAGNOS Announces Voting Results of Meeting of Shareholders

BROSSARD, Quebec, Sept. 25, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence (AI) technologies, announces the voting results of the annual meeting of the shareholders held earlier today.

Mr. André Larente, Mr. Robert Dunn, Mr. Michael Braeuel and Mr. Philippe Couillard were elected as directors to hold office until the closing of the next annual meeting of the shareholders.

Grant Thornton LLP was appointed auditor of the Corporation for the year ending March 31, 2026.

DIAGNOS also announces a grant of an aggregate number of 1,100,000 stock options to two directors of the Corporation in replacement for 600,000 stock options which expired on August 26, 2025, and 500,000 stock options expiring September 28, 2025. The date of the grant is September 25, 2025. The expiry date to which the stock options can be exercised is September 25, 2030. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of the stock options granted has been established at $0.26 per common share. The grant remains subject to regulatory compliance including TSX Venture exchange acceptance.

Monies quoted in this press release shall be stated in lawful money of Canada.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

Additional information is available at www.diagnos.com and www.sedarplus.com.

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.